Picture of GeneDx Holdings logo

WGS — GeneDx Holdings News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMid CapMomentum Trap

GeneDx Holdings Corp expected to post a loss of 30 cents a share - Earnings Preview

* GeneDx Holdings Corp  WGS.OQ   WGS.O  is expected to show
a rise
in quarterly revenue when it reports  results on July 30 for the
period ending June 30 2024
    * The Stamford Connecticut-based  company is expected to
report a
21.8% increase in revenue to $59.311 million from $48.71 million
a year ago, according to the mean estimate from 5 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for GeneDx Holdings Corp is
for a
loss of 30 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for GeneDx
Holdings
Corp is $35.00​, above​ its last closing price of $32.72. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -0.65       -0.67      -0.33     Beat    50.5
 Dec. 31 0001  -0.64       -0.75      -0.69     Beat    8.4
 Sep. 30 2023  -1.28       -1.31      -0.82     Beat    37.4​
 Jun. 30 2023  -1.41       -1.31      -1.64     Missed  -24.9
 ​​Mar.        -1.36       -2.14      -2.44     Missed  -14.2
 31 2023                                                
 Jan. 1 0001   -4.84       -5.28      -8.25     Missed  -56.2​
 Jan. 1 0001   -6.91       -7.01      -6.60     Beat    5.9
 Jun. 30 2022  -6.61       -6.93      -8.25     Missed  -19
 This summary was machine generated July 26 at 21:54 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on GeneDx Holdings

See all news